Programmable ROS modulation by nanomedicine for rheumatoid arthritis treatment
Source abstract
Abstract
Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by persistent synovial inflammation and progressive joint destruction. Extensive studies have demonstrated that reactive oxygen species (ROS) play a critical role in the pathogenesis and progression of RA. Imbalanced ROS not only aggravate synovial inflammation and cartilage degradation but also disrupt immune homeostasis. In recent years, nanotechnology-based strategies for regulating ROS have provided new insights into the precise treatment of RA. This review systematically summarizes ROS-centered nanotherapeutic systems applied in RA therapy, including ROS-scavenging nanosystems, ROS-responsive nanosystems, ROS-scavenging and responsive composite nanosystems, and ROS-augmenting nanosystems. Furthermore, the review highlights the advantages of ROS-modulating nanosystems in reshaping the immune microenvironment, restoring redox balance, and achieving combination therapy and theranostic integration, while also addressing challenges related to biosafety, controllability, and clinical translation. Overall, programmable ROS-modulating nanotherapeutic strategies offer new directions and theoretical foundations for the precise treatment of RA. • Programmable ROS modulation framed as a core strategy for RA nanotherapy. • Link ROS biology, inflammatory pathways and nanomaterial design principles. • Summarize ROS-scavenging, ROS-responsive, hybrid and ROS-augmenting systems. • Discuss translational challenges and design cues for clinical RA nanomedicine.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Rheumatoid Arthritis Research and Therapies · Nanoplatforms for cancer theranostics · Spondyloarthritis Studies and Treatments
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. Successes and failures of chemokine-pathway targeting in rheumatoid arthritis10.1038/nrrheum.2015.157 ↗
2. Rheumatoid arthritis10.7326/AITC201901010 ↗
3. Magnesium-based micromotors as hydrogen generators for precise rheumatoid arthritis therapy10.1021/acs.nanolett.0c04438 ↗
4. Mechanisms of joint destruction in rheumatoid arthritis — immune cell–fibroblast–bone interactions10.1038/s41584-022-00793-5 ↗
5. Challenges in the treatment of rheumatoid arthritis10.1016/j.autrev.2019.05.007 ↗
6. Mechanisms of lung disease development in rheumatoid arthritis10.1038/s41584-019-0275-x ↗
7. How early in the course of rheumatoid arthritis does the excess cardiovascular risk appear?10.1136/annrheumdis-2012-201334 ↗
8. Increased cardiovascular risk in rheumatoid arthritis: mechanisms and implications
9. Rheumatoid arthritis: extra-articular manifestations and comorbidities10.1016/j.autrev.2021.102776 ↗
10. The pathogenesis of rheumatoid arthritis10.1056/NEJMra1004965 ↗
11. Rheumatoid arthritis10.1016/S0140-6736(10)60826-4 ↗
12. Quantification of the influence of cigarette smoking on rheumatoid arthritis: results from a population based case-control study, using incident cases10.1136/ard.62.9.835 ↗
13. Osteoporosis and fractures in rheumatoid arthritis10.1097/BOR.0000000000000789 ↗
14. Vascular disease in rheumatoid arthritis: from subclinical lesions to cardiovascular risk10.1016/j.ejim.2008.09.005 ↗
15. T-cells interact with B cells, dendritic cells, and fibroblast-like synoviocytes as hub-like key cells in rheumatoid arthritis10.1016/j.intimp.2019.03.008 ↗
16. The many facets of macrophages in rheumatoid arthritis10.1016/j.bcp.2019.03.029 ↗
17. Plasma lipid peroxidation and antioxidant levels in patients with rheumatoid arthritis10.1002/cbf.1055 ↗
18. Reactive oxygen species (ROS) scavenging biomaterials for anti-inflammatory diseases: from mechanism to therapy10.1186/s13045-023-01512-7 ↗
19. Oxidative stress: a concept in redox biology and medicine10.1016/j.redox.2015.01.002 ↗
20. Hypoxia--a key regulator of angiogenesis and inflammation in rheumatoid arthritis10.1038/nrrheum.2011.205 ↗
21. HIF1alpha inhibition facilitates Leflunomide-AHR-CRP signaling to attenuate bone erosion in CRP-aberrant rheumatoid arthritis10.1038/s41467-019-12163-z ↗
22. Macrophage M1/M2 polarization and rheumatoid arthritis: a systematic review10.1016/j.autrev.2019.102397 ↗
23. Macrophage membrane‐reversibly cloaked nanotherapeutics for the anti‐inflammatory and antioxidant treatment of rheumatoid arthritis10.1002/smtd.202300667 ↗
24. Role of reactive oxygen species and mitochondrial damage in rheumatoid arthritis and targeted drugs10.3389/fimmu.2023.1107670 ↗
25. Strategies toward rheumatoid arthritis therapy; the old and the new10.1002/jcp.27860 ↗
26. The emerging safety profile of JAK inhibitors in rheumatic disease10.1038/nrrheum.2017.23 ↗
27. The promise of precision medicine in rheumatology10.1038/s41591-022-01880-6 ↗
28. Mitochondrial reactive oxygen species (ROS) and ROS-induced ROS release10.1152/physrev.00026.2013 ↗
29. Failure of anti-TNF treatment in patients with rheumatoid arthritis: the pros and cons of the early use of alternative biological agents10.1016/j.autrev.2019.102398 ↗
30. Management of rheumatoid arthritis: an overview10.3390/cells10112857 ↗
31. Nanotherapeutic approaches for the treatment of rheumatoid arthritis10.1002/wnan.157 ↗
32. Nanomedicine - advantages for their use in rheumatoid arthritis theranostics10.1016/j.jconrel.2019.11.008 ↗
33. Folate-targeted nanoparticles for rheumatoid arthritis therapy10.1016/j.nano.2015.12.365 ↗
34. Nano based drug delivery systems: recent developments and future prospects10.1186/s12951-018-0392-8 ↗
35. Nanomedicine in cancer therapy10.1038/s41392-023-01536-y ↗
36. Utilization of nanoparticle technology in rheumatoid arthritis treatment10.1016/j.biopha.2016.03.004 ↗
37. A multifunctional nano-therapeutic platform based on octahedral yolk-shell Au NR@CuS: Photothermal/photodynamic and targeted drug delivery tri-combined therapy for rheumatoid arthritis10.1016/j.biomaterials.2021.121088 ↗
38. PRP-Chitosan thermoresponsive hydrogel combined with Black phosphorus nanosheets as injectable biomaterial for biotherapy and phototherapy treatment of rheumatoid arthritis10.1016/j.biomaterials.2020.119851 ↗
39. Dexamethasone palmitate nanoparticles: an efficient treatment for rheumatoid arthritis10.1016/j.jconrel.2019.01.015 ↗
40. Nanomedicines for the treatment of rheumatoid arthritis: state of art and potential therapeutic strategies10.1016/j.apsb.2021.03.013 ↗
41. Toxicology of engineered nanomaterials: focus on biocompatibility, biodistribution and biodegradation10.1016/j.bbagen.2010.04.007 ↗
42. Neutrophil membrane-coated nanoparticles inhibit synovial inflammation and alleviate joint damage in inflammatory arthritis10.1038/s41565-018-0254-4 ↗
43. Reactive oxygen and nitrogen species – “nanosweeper” for rheumatoid arthritis theranostics by macrophage reprogramming10.1021/acsami.4c16772 ↗
44. Tannic acid-based biomimetic nanomedicine with pathological reactive oxygen species-responsive cargo release for relieving inflammation in rheumatoid arthritis10.1021/acsami.4c11494 ↗
45. Photosensitizers used in the photodynamic therapy of rheumatoid arthritis10.3390/ijms20133339 ↗
46. Integrated nanomaterials for non-invasive photothermal therapy of rheumatoid arthritis10.1016/j.drudis.2021.04.026 ↗
47. ROS and ROS‐Mediated cellular signaling10.1155/2016/4350965 ↗
48. Critical role for calcium mobilization in activation of the NLRP3 inflammasome10.1073/pnas.1117765109 ↗
49. Protein kinase Cdelta selectively regulates protein kinase D-dependent activation of NF-kappaB in oxidative stress signaling10.1128/MCB.24.7.2614-2626.2004 ↗
50. Reactive oxygen species-activated Akt/ASK1/p38 signaling pathway in nickel compound-induced apoptosis in BEAS 2B cells10.1021/tx9003193 ↗
51. p38 MAPK inhibitors attenuate pro-inflammatory cytokine production and the invasiveness of human U251 glioblastoma cells10.1007/s11060-012-0875-7 ↗
52. NADPH oxidase-dependent reactive oxygen species mediate amplified TLR4 signaling and sepsis-induced mortality in Nrf2-deficient mice10.4049/jimmunol.0902315 ↗
53. Nanomedicine: an emerging era of theranostics and therapeutics for rheumatoid arthritis10.1093/rheumatology/kez286 ↗
54. Nanomedicine is more than a supporting role in rheumatoid arthritis therapy10.1016/j.jconrel.2023.02.035 ↗
55. Nanomedicine targeted anti-inflammatory therapy to deal with the ‘crux’ of rheumatoid arthritis10.1080/1061186X.2024.2315475 ↗
56. Nanomedicine – advantages for their use in rheumatoid arthritis theranostics10.1016/j.jconrel.2019.11.008 ↗
57. Nanomedicine for the treatment of rheumatoid arthritis10.1021/acs.molpharmaceut.0c00295 ↗
58. A supramolecular assembly strategy for the treatment of rheumatoid arthritis with ultrasound-augmented inflammatory microenvironment reprograming10.1016/j.biomaterials.2024.123006 ↗
59. Neutrophil activation markers and rheumatoid arthritis treatment response to the JAK1/2 inhibitor baricitinib10.1002/art.43042 ↗
60. Synovial microenvironment-influenced mast cells promote the progression of rheumatoid arthritis10.1038/s41467-023-44304-w ↗
61. ROS and diseases: role in metabolism and energy supply10.1007/s11010-019-03667-9 ↗
62. Amelioration of the rheumatoid arthritis microenvironment using celastrol-loaded silver-modified ceria nanoparticles for enhanced treatment10.1186/s12951-025-03388-w ↗
63. Oxidative stress, consequences and ROS mediated cellular signaling in rheumatoid arthritis10.1016/j.cbi.2017.12.024 ↗
64. Ceria-based nanotheranostic agent for rheumatoid arthritis10.7150/thno.49069 ↗
65. Simultaneous blood-brain barrier crossing and protection for stroke treatment based on edaravone-loaded ceria nanoparticles10.1021/acsnano.8b01994 ↗
66. Recent advances in nanozyme research10.1002/adma.201805368 ↗
67. Nanomaterials with enzyme-like characteristics (nanozymes): next-generation artificial enzymes (II)10.1039/C8CS00457A ↗
68. Mn-Ce symbiosis: nanozymes with multiple active sites facilitate scavenging of Reactive Oxygen Species (ROS) based on electron transfer and confinement anchoring10.1002/anie.202416686 ↗
69. A thrombin-activated peptide-templated nanozyme for remedying ischemic stroke via thrombolytic and neuroprotective actions10.1002/adma.202470077 ↗
70. Nanozymes: classification, catalytic mechanisms, activity regulation, and applications10.1021/acs.chemrev.8b00672 ↗
71. Deep eutectic solvents-Hydrogels for the topical management of rheumatoid arthritis10.1016/j.jconrel.2023.01.050 ↗
72. Synergistic oxygen generation and reactive oxygen species scavenging by manganese Ferrite/Ceria Co-decorated nanoparticles for rheumatoid arthritis treatment10.1021/acsnano.8b08785 ↗
73. A MgFe-LDH nanosheet-incorporated smart thermo-responsive hydrogel with controllable growth factor releasing capability for bone regeneration10.1002/adma.202206545 ↗
74. Anti-acidification and immune regulation by nano-ceria-loaded Mg-Al layered double hydroxide for rheumatoid arthritis therapy
75. Cytokine regulation and fast inflammation resolution in early rheumatoid arthritis by cerium-modified gold nanoclusters10.1021/acsami.1c22831 ↗
76. Arthritic microenvironment actuated nanomotors for active rheumatoid arthritis therapy
77. Multifunctional Janus nanoplatform for efficiently synergistic theranostics of rheumatoid arthritis10.1021/acsnano.2c11777 ↗
78. MCL restrained ROS/AKT/ASAH1 pathway to therapy tamoxifen resistance breast cancer by stabilizing NRF210.1111/cpr.13700 ↗
79. Microneedles loaded with cerium-manganese oxide nanoparticles for targeting macrophages in the treatment of rheumatoid arthritis10.1186/s12951-024-02374-y ↗
80. Multifunctional nanoplatform for mild microwave-enhanced thermal, antioxidative, and chemotherapeutic treatment of rheumatoid arthritis10.1021/acsami.2c19198 ↗
81. Targeted silver nanoparticles for rheumatoid arthritis therapy via macrophage apoptosis and Re-polarization10.1016/j.biomaterials.2020.120390 ↗
82. Ferrihydrite nanoparticles alleviate rheumatoid arthritis by nanocatalytic antioxidation and oxygenation10.1021/acs.nanolett.3c02743 ↗
83. Nanozyme-reinforced hydrogel as a H(2)O(2)-driven oxygenerator for enhancing prosthetic interface osseointegration in rheumatoid arthritis therapy10.1038/s41467-022-34481-5 ↗
84. Synergistic rheumatoid arthritis therapy by interrupting the detrimental feedback loop to orchestrate hypoxia M1 macrophage polarization using an enzyme-catalyzed nanoplatform
85. Polydopamine and its derivative materials: synthesis and promising applications in energy, environmental, and biomedical fields10.1021/cr400407a ↗
86. Evaluation of reactive oxygen species scavenging of polydopamine with different nanostructures
87. A responsive nanoplatform with molecular and structural imaging capacity for assisting accurate diagnosis of early rheumatoid arthritis
88. Synergistic chemotherapy/PTT/oxygen enrichment by multifunctional liposomal polydopamine nanoparticles for rheumatoid arthritis treatment
89. Inflammation targeting and responsive multifunctional drug-delivery nanoplatforms for combined therapy of rheumatoid arthritis10.1002/smll.202500113 ↗
90. Targeted delivery of NO donor and ROS scavenger for synergistic treatment of rheumatoid arthritis10.1016/j.biopha.2024.116540 ↗
91. Beneficial properties of green tea catechins10.3390/ijms21051744 ↗
92. New insights into the mechanisms of polyphenols beyond antioxidant properties; lessons from the green tea polyphenol, epigallocatechin 3-gallate10.1016/j.redox.2013.12.022 ↗
93. Reactive oxygen species-responsive dendritic cell-derived exosomes for rheumatoid arthritis10.1016/j.actbio.2021.04.026 ↗
94. Assembly of metal-Phenolic/Catecholamine networks for synergistically anti-inflammatory, antimicrobial, and anticoagulant coatings10.1021/acsami.8b14409 ↗
95. Rosmarinic acid nanomedicine for rheumatoid arthritis therapy: targeted RONS scavenging and macrophage repolarization10.1016/j.jconrel.2023.09.012 ↗
96. Alginate nanogel-embedded liposomal drug carriers facilitate drug delivery efficiency in arthritis treatment
97. Ultrasmall iron-quercetin metal natural product nanocomplex with antioxidant and macrophage regulation in rheumatoid arthritis10.1016/j.apsb.2022.11.020 ↗
98. Global, regional, and national incidence of six major immune-mediated inflammatory diseases: findings from the global burden of disease study 2019
99. Modular acid-activatable acetone-based ketal-linked nanomedicine by dexamethasone prodrugs for enhanced anti-rheumatoid arthritis with low side effects10.1021/acs.nanolett.9b05340 ↗
100. Prussian blue nanoparticles: synthesis, surface modification, and biomedical applications10.1016/j.drudis.2020.05.014 ↗